Effects of A1AT on PCSK9 expression and function
Effects of A1AT on PCSK9 expression and function
批准号:
10224753
负责人:
Dayami Lopez
金额:
$37.0万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-08-09 至 2023-07-31
关键词:
AccountingAffectAllelesAmericanArterial Fatty StreakAtherosclerosisBindingBiologicalBlood CirculationCardiovascular DiseasesCause of DeathCell membraneCellsCessation of lifeCholesterolComplexDeletion MutationDevelopmentDiagnostic testsDiseaseEstrogensExcisionHeart DiseasesHepaticHormonesIn VitroInsulinKnowledgeLDL Cholesterol LipoproteinsLaboratoriesLeadLinkLiver diseasesLow Density Lipoprotein ReceptorLow-Density LipoproteinsLung diseasesMediator of activation proteinMicroRNAsMolecularMyocardial InfarctionOutcomePathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstancePlasmaPopulationPropertyProprotein ConvertasesProtein RegionProteinsRecommendationRegulationResearch Project GrantsResearch ProposalsRisk FactorsRoleSR-B proteinsSpecificitySubtilisinsTestingTherapeuticTranscriptTriiodothyronineWomanalpha 1-Antitrypsinalternative treatmentbasecardiovascular disorder riskdesigndisabilityexperimental studyhypercholesterolemiainhibitor/antagonistmenmutantnovelnovel diagnosticsparticlepreventreceptorside effect
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Heart disease is the principal cause of death and disability for both men and women in the US accounting
for 40% of all annual deaths. A high cholesterol level, especially of low density lipoprotein (LDL), is a well-known
risk factor for this disease. The key atherogenic property of LDL particles involves the formation of
atherosclerotic plaques. Since the hepatic LDL receptor is the major determinant of plasma LDL-cholesterol
levels, a greater understanding of the regulatory mechanisms that control the expression of the LDL receptor is
essential. Proprotein convertase subtilisin/kexin-9 (PCSK9) is a well-known indirect regulator of plasma LDL
levels by controlling the number of LDL receptor molecules expressed at the plasma membrane. Preliminary
studies in our laboratory suggest that alpha-1-antitrypsin (A1AT) directly interacts with PCSK9 in the medium of
cells and prevents the formation of PCSK9/LDL receptor complexes in vitro. A1AT also promotes the removal
of PCSK9 from the medium of the cells, but the mechanism for this removal is currently unknown. The long-term
objective of this research project is to characterize the molecular mechanisms involved in the A1AT-dependent
regulation of PCSK9 expression and function. The major impact of this project will be the identification of an
endogenous inhibitor of PCSK9 could lead to the development of diagnostic tests to identify patients and provide
them with the best and safest treatment options. Also, this inhibitor could become an alternative treatment for
patients that develop intolerance to currently available anticholesterolemic drugs. Based on this, we
hypothesized that the levels of LDL receptor protein that is available to bind and remove LDL from the circulation
are conditioned to the ratio between A1AT and PCSK9. In this research proposal, we will test this hypothesis
through the following specific aims: Aim I: To find common regulators of A1AT and PCSK9 expression; Aim
II: To detect critical protein regions in A1AT that influences PCSK9 expression/function; Aim III: To identify the
pathway(s) involved in the internalization of PCSK9/A1AT complexes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effects of A1AT on PCSK9 expression and function
-
批准号:10458571
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2019
-
负责人:Dayami Lopez
-
依托单位:
海外基金